| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46.
The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion.
The increase was primarily due to growth contributions from several of our acquired products, key in-line products, and recent commercial launches, which more than offset both an expected decline in Comirnaty.
Also Read: Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study.
Excluding contributions from Comirnaty and Paxlovid, revenues reached $12.8 billion, increased 14% operationally.
In the second quarter of 2024, Comirnaty’s revenues of $195 million declined by 87%. Paxlovid revenues increased 79% to $251 million.
Vyndaqel family drugs generated sales of $2.46 billion, up 68%. Eliquis, a blood thinner drug, generated sales of $3.92 billion, up 9%.
Albert Bourla, Chairman and Chief Executive Officer, stated, “Notably, we achieved exceptional growth in our Oncology portfolio, with strong revenue contribution from our legacy-Seagen products.”
“In the second quarter, for example, we achieved year-over-year revenue growth for the first time since the fourth quarter of 2022 when our COVID revenues peaked,” Bourla added.
In May, Pfizer launched a multi-year cost-cutting initiative to save approximately $1.5 billion by the end of 2027.
Guidance: Pfizer updates its 2024 revenue forecast to $59.5 billion—$62.5 billion, compared to prior guidance of $58.5 billion—$61.5 billion and consensus of $60.7 billion.
The company’s updated guidance includes approximately $8.5 billion (vs. $8 billion expected earlier) in anticipated revenues for Comirnaty and Paxlovid, approximately $5 billion and $3.5 billion, respectively.
Pfizer expects 2024 operational revenue growth of 9%- 11% year over year, up from 8%- 10% provided on January 30, 2024.
Pfizer expects 2024 adjusted EPS of $2.45-$2.65 compared to prior guidance of $2.15-$2.35 and consensus of $2.37.
Price Action: PFE stock is up 1.60% at $31.21 during the premarket session at the last check on Tuesday.
Read Next:
Photo via Wikimedia Commons
Posted In: PFE
